|
CO.DON AG: EU-approved medicinal product
receives vote for indication extension for use in
adolescents
Teltow (pta001/22.05.2021/00:01) - Teltow /
Leipzig, 21 May 2021 - CO.DON AG (ISIN:
DE000A1K0227) received today the positive vote of
the CHMP (Committee for Medicinal Products for
Human Use) of the EMA (European Medicines Agency)
on the approval of the application for the
indication extension of the EU-wide approved
medicinal product for human use "Spherox -
Spheroids from human autologous matrix-associated
chondrocytes" for the use in adolescents.
The CHMP's assessment is the basis for the
European Commission's decision on the EU-wide
authorisation of the indication extension. In the
past, the European Commission followed the
recommendations of the CHMP in the vast majority of
applications.
With the expanded indication for the EU, the
treatment of symptomatic articular cartilage
defects of ICRS Grade III or IV of the femoral
condyle and the patella of the knee with defect
sizes of up to 10 cm^2 is now also possible in
adolescents with closed growth plates in addition
to adult patients.
Notifying person: Tilman Bur, Management
Board
Contact Matthias Meißner Director
Corporate Communications Investor Relations /
Public Relations T: +49 (0)341 99190 330 F: +49
(0)341 99190 309 E: ir@codon.de
emitter: CO.DON AG address: Warthestraße
21, 14513 Teltow country: Germany contact person:
Matthias Meißner phone: +49 341 99190330
e-mail: ir@codon.de website: www.codon.de ISIN(s):
DE000A1K0227 (share) stock exchanges: regulated
market in Frankfurt; free market in Stuttgart, free
market in Hamburg, free market in Dusseldorf; open
market in Berlin, Tradegate source:
http://adhoc.pressetext.com/news/1621634460297
|